Nanotechnology

Content

• Executive Summary
  • Nanotechnology: Driving Change in Pharmaceutical R & D
  • Nanotechnology: Drug Research & Development
  • Nanotechnology: Nanoformulations & Nanocarriers
  • Nanotechnology: Diagnostics & Imaging
  • Nanotechnology: Therapeutic Applications
  • Nanotechnology: Regulations, Patents and Scientific Publications
  • Nanotechnology: Challenges, Opportunities & Future Applications
• Chapter 1 Driving Change in Pharmaceutical R & D
  • Summary
  • Defining Nanotechnology
  • Nanotechnology Funding
  • Nanotechnology Evolution
  • Nanotechnology in The Pharma Industry
  • Nanotechnology Start-up Companies
  • Nanotechnology in Academia
  • Drivers of Nanotechnology Research
  • Report Outline
• Chapter 2 Drug Research & Development
  • Summary
  • Introduction
  • Nanotechnology in Drug Discovery & Development
  • Nanotools for Drug Discovery & Development
  • Application of Nanotools in Drug Discovery & Development
  • Nanoscaffolding
  • Nanoarrays
  • Bioforce Nanosciences
  • Nanogen
  • Nanotubes & Nanosensors
  • Nano-Proprietary Inc
  • Carbon Nanotechnologies Inc
  • Nanowires & Cantilevers
  • Microfluidic Lab-on-A-Chip
  • Caliper Life Sciences
  • Nanofluidic Lab-on-A-Chip
  • Quantum Dots
  • Evident Technologies
  • Biomarker Harvesting
  • Instruments for Nanodetection and Analysis
  • Atomic Force Microscopy
  • Surface Plasmon Resonance
  • Instruments for Nanofabrication
  • Dip Pen Nanolithography (Dpn)
  • Conclusions
• Chapter 3 Nanoformulations & Nanocarriers
  • Summary
  • Introduction
  • Leading Companies in Nanoformulations
  • Approved Nanoformulations
  • Dendrimers
  • Liposomal Formulations
  • Pegylated Liposomal Formulations
  • Nanocrystal Formulations
  • Nanoparticle Formulations
  • Developmental Nanoformulations
  • Protein-Stabilized Liposomal Formulations
  • Controlled-Release Liposomal Formulations
  • New Controlled-Release Nanoparticle and Nanosphere Formulations
  • Magnetic Nanoparticle Formulations
  • Novel Nanomaterials for Drug Delivery
  • Nanobombs
  • Nanoshells
  • Nanotubes
  • Conclusions
• Chapter 4 Diagnostics & Imaging
  • Summary
  • Introduction
  • Nanoarrays
  • Cystalline Nanoarrays
  • Nanodevices
  • Magnetic Nanoparticles, Nanocapsules and Nanocells
  • Nanoparticle Barcodes
  • Multifunctional Nanoparticles and Nanocells
  • Gold Nanoparticles
  • Fluorescent Nanoparticles
  • Fluorescent Nanocrystals
  • Nanoscale Contrast Agents
  • Multiplex Imaging Agents/Therapeutics
  • Conclusions
• Chapter 5 Therapeutic Applications
  • Summary
  • Introduction
  • Nanotechnology in Cancer
  • Research
  • in Vivo Imaging
  • Molecular Imaging & Diagnostics
  • Drug Delivery
  • Cancer Conclusions
  • Nanotechnology in Cardiovascular Disease
  • Therapeutic Research
  • Molecular Imaging & Diagnostics
  • Tissue Engineering & Regenerative Medicines
  • Medical Devices
  • Drug Delivery
  • Cardiovascular Conclusions
  • Nanotechnology in CNS
  • Research & Development
  • Diagnostics & Imaging
  • Drug Delivery
  • Neurodevices and Nanowires
  • CNS Conclusions
  • Overall Conclusions
• Chapter 6 Regulations, Patents and Scientific
  • Publications
  • Summary
  • Nanotechnology Guidelines
  • Patentability and Publications
  • Nanotechnology Patents
  • Nanotechnology-Based Publications
  • Conclusions
• Chapter 7 Challenges, Opportunities and Future
  • Applications
  • Summary
  • Introduction
  • Challenges in Adopting Nanotechnology
  • Regulations
  • Legal, Political and Ethical Issues
  • Public Perception of Nanotechnology
  • Multidisciplinary Infrastructure
  • Intellectual Property
  • Commerciality of Existing Nanotechnology and Medicines
  • Opportunities for Adopting Nanotechnology
  • Product Repositioning
  • New Imaging Agents for Early Disease Detection
  • Point-of-Care Diagnostics
  • Personalized Medicines
  • Implementing Nanotechnology in The Pharma Industry
  • Competitive Strategies
  • Astrazeneca
  • Bristol-Myers Squibb
  • Glaxosmithkline
  • Novartis
  • Roche
  • Pfizer
  • Elan Corporation
  • Genentech
  • Ge Healthcare
  • Siemens Medical Solutions
  • Abraxis Biosciences
  • Psividia Limited
  • Starpharma Holdings Ltd
  • Alliances & Licensing
  • Future Impact of Nanotechnology on Drug Discovery & Development
• Chapter 8 Appendix
  • Glossary
  • Bibliography
  • Index
  • Endnotes
• List of Figures
  • Figure 1.1: Nanometer Scale
  • Figure 1.2: Top-down and Bottom-up Nanotechnology Approach
  • Figure 1.3: Applications of Nanotechnology
  • Figure 1.4: Global Nanotechnology Funding, 2003
  • Figure 1.5: Global Nanotechnology Market by 2015
  • Figure 1.6: Evolution of Nanotechnology 2000-2020
  • Figure 1.7: Evolution of The Nanotechnology Market
  • Figure 1.8: Nanotechnology Applications in The Pharma Industry
  • Figure 2.9: Nanotechnology Innovating The R & D Process
  • Figure 2.10: Applications of Nanotechnologies in Drug Discovery & Development
  • Figure 2.11: Tem of Native Collagen Fibers and Nanoscaffolding
  • Figure 2.12: Array of Probes on Nanoarray
  • Figure 2.13: Bead Nanoarrays from Nanovic
  • Figure 2.14: Nanochip 400 System
  • Figure 2.15: Nanosensors for Analyte Detection
  • Figure 2.16: Nanowires and Cantilevers for Nanodetection and Multiplexing
  • Figure 2.17: Scanning Electron Microscope Image of A Five-Nozzle M3 Emitter
  • Figure 2.18: Evolution of Microfluidics and Nanofluidics in The Pharma Industry
  • Figure 2.19: Nanoparticle Bioconjugate Harvesting Platform
  • Figure 2.20: Schematic of Atm Technology
  • Figure 2.21: Afm Images Measuring Real-Time Cell Activity
  • Figure 2.22: Schematic of Spr Technology
  • Figure 2.23: Schematic of Dpn Technology and Its Applications
  • Figure 3.24: Nanoformulations Driving Drug Delivery
  • Figure 3.25: Dendrimer Structure
  • Figure 3.26: Dendrimer Delivery Platform
  • Figure 3.27: Dauxoxome Liposomal Formulation
  • Figure 3.28: Doxil Liposomal Formulation Versus Non-Liposomal Formulation
  • Figure 3.29: Enhanced Bioavailability and Absorption Rate with Nanocrystals Technology
  • Figure 3.30: Abraxane Nab Technology - Photosphere
  • Figure 3.31: Micellar Nanoparticles (Mnp)
  • Figure 3.32: Controlled-Release Liposomal Formulations
  • Figure 3.33: Fullerene Structures A) C-60 and B) C-70
  • Figure 3.34: Aurolase Treated Mice Versus Sham Treatment
  • Figure 3.35: Carbon Nanotubes
  • Figure 4.36: Nanotechnologies Advancing Diagnostics and Imaging
  • Figure 4.37: Virichip Virus Detection Platform
  • Figure 4.38: S-Layer Technology Platform
  • Figure 4.39: Sensation Virus Detection Platform
  • Figure 4.40: Bionanochannel Bacterial Detection Platform
  • Figure 4.41: Biobarcode Assays for The Detection of Psa
  • Figure 4.42: Biosensor Biobarcode
  • Figure 4.43: Oxonica's Nanoplex Biotag and Poc Diagnostic
  • Figure 4.44: Aurovist Microct Image
  • Figure 4.45: Nanostrings Nanoparticle Barcoding
  • Figure 4.46: Schematic of Fluorescent A) Lanthanide Structure and B) Lanthanide Nanoparticles
  • Figure 4.47: Qdot Nanocrystal Structure
  • Figure 4.48: Trilite Emission Spectra
  • Figure 4.49: Viral Capsids as Imaging Carriers
  • Figure 4.50: Multifunctional Nanocarriers for Detection, Diagnosis and Treatment
  • Figure 4.51: Nanotechnology Improving Molecular Detection and Diagnosis of Cancer
  • Figure 5.52: Application of Nanotechnology in Cancer, Cardiovascular and CNS Disorders
  • Figure 5.53: Cyberkinetic's Brain Gate
  • Figure 6.54: Federal Regulators Addressing Different Aspects of Nanotechnology
  • Figure 6.55: Japanese Governmental System for Science & Technology
  • Figure 6.56: Worldwide Nanopatents 1995-2003
  • Figure 6.57: Worldwide Nanopatents by Region of Applicant and Inventor
  • Figure 6.58: Worldwide Nanoscientific Publications per World Region
  • Figure 6.59: Worldwide Nanoscientific Publications per Country and Subfield 1999-2004
  • Figure 7.60: Future Impact of Nanotools on Pharmaceuticals and Healthcare
  • Figure 7.61: Health Care Trends to 2020 - Glaxosmithkline
• List of Tables
  • Table 1.1: Leading Nanotechnology Start-up Companies
  • Table 1.2: Leading Nanotechnology Institutes, Forums and Networking Organizations
  • Table 2.3: Key Attributes of Puramatrix Versus Other Ecms
  • Table 2.4: Leading Lab-on-Chip (Loc) and Microfluidic Manufacturers
  • Table 2.5: Leading Manufacturers of Qdots
  • Table 2.6: Advantages of Dpn Versus Other Top-down and Bottom-up Fabrication Technologies
  • Table 3.7: Approved Nanoformulations
  • Table 3.8: Leading Nanoformulation Companies
  • Table 4.9: Leading Diagnostics and Imaging Companies Evaluating Nanotechnology
  • Table 5.10: Nano-Enabled Delivery System for Cancer Therapeutics
  • Table 5.11: Approved & Developmental Cancer Nanomedicines
  • Table 5.12: Nanotechnology Application in Cardiovascular Devices
  • Table 5.13: Nano-Enabled Delivery System under Evaluation for Cardiovascular Therapies
  • Table 5.14: Nano-Enabled Delivery System under Evaluation for CNS Therapies
  • Table 7.15: Recent Alliances and Licensing Deals in Nanotechnology